Koushi Hidaka

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6681429/publications.pdf

Version: 2024-02-01

54	1,491	304602	330025
papers	citations	22 h-index	37 g-index

55	55	55	1391
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	7-Aminocoumarin-4-acetic Acid as a Fluorescent Probe for Detecting Bacterial Dipeptidyl Peptidase Activities in Water-in-Oil Droplets and in Bulk. Analytical Chemistry, 2022, 94, 2416-2424.	3.2	10
2	Characterization of JC Polyomavirus Derived from COS-IMRb Cells. Japanese Journal of Infectious Diseases, 2021, 74, 48-53.	0.5	1
3	Exploration of Active Site-Directed Plasmin Inhibitors: Beyond Tranexamic Acid. Processes, 2021, 9, 329.	1.3	3
4	Acquired Removability of Aspartic Protease Inhibitors by Direct Biotinylation. Bioconjugate Chemistry, 2019, 30, 1979-1985.	1.8	1
5	A Novel Prodrug of a Î³â€Glutamylcyclotransferase Inhibitor Suppresses Cancer Cell Proliferation inâ€...vitro and Inhibits Tumor Growth in a Xenograft Mouse Model of Prostate Cancer. ChemMedChem, 2018, 13, 155-163.	1.6	12
6	Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine. Journal of Medicinal Chemistry, 2018, 61, 5138-5153.	2.9	12
7	Deciphering the mechanism of potent peptidomimetic inhibitors targeting plasmepsins â€“ biochemical and structural insights. FEBS Journal, 2018, 285, 3077-3096.	2.2	11
8	Establishment of COSâ€JC cells persistently producing archetype JC polyomavirus. Microbiology and Immunology, 2018, 62, 524-530.	0.7	2
9	Evaluation of novel protease inhibitors against darunavirâ€resistant variants of HIV type 1. FEBS Open Bio, 2017, 7, 88-95.	1.0	3
10	X-ray crystal structure of plasmin with tranexamic acidâ€“derived active site inhibitors. Blood Advances, 2017, 1, 766-771.	2.5	25
11	Active site-directed plasmin inhibitors: Extension on the P2 residue. Bioorganic and Medicinal Chemistry, 2016, 24, 545-553.	1.4	9
12	Oligomerization of neutral peptides derived from the JC virus agnoprotein through a cysteine residue. Amino Acids, 2015, 47, 2205-2213.	1.2	4
13	Aqueous microwave-assisted solid-phase peptide synthesis using Fmoc strategy. III: Racemization studies and water-based synthesis of histidine-containing peptides. Amino Acids, 2014, 46, 2347-2354.	1.2	24
14	Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1698-1701.	1.0	4
15	Structureâ€“activity relationship study of BACE1 inhibitors possessing a chelidonic or 2,6-pyridinedicarboxylic scaffold at the P2 position. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 618-623.	1.0	12
16	A Fluorogenic Probe for Î³â€Glutamyl Cyclotransferase: Application of an Enzymeâ€Triggered Oâ€toâ€N Acyl Migrationâ€Type Reaction. ChemBioChem, 2013, 14, 2110-2113.	1.3	10
17	Novel BACE1 inhibitors possessing a 5-nitroisophthalic scaffold at the P2 position. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4640-4644.	1.0	19
18	Structural Insights into the Activation and Inhibition of Histo-Aspartic Protease from Plasmodium falciparum. Biochemistry, 2011, 50, 8862-8879.	1.2	15

#	Article	IF	Citations
19	Crystal structures of the free and inhibited forms of plasmepsin I (PMI) from Plasmodium falciparum. Journal of Structural Biology, 2011, 175, 73-84.	1.3	35
20	Structure-guided design and synthesis of <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:mmultiscripts><mml:mrow><mml:mtext>P</mml:mtext></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:none /><mml:none /><mml:mrow><mml:mo>â€²</mml:mo></mml:mrow></mml:mmultiscripts></mml:mrow></mml:math> position 1-phenylcycloalkylamine-derived pentapeptidic BACE1 inhibitors. Bioorganic and Medicinal Che	1.4	21
21	Development of [Ile⁴⁰]HTLVâ€I protease inhibition assay using novel fluorogenic and chromogenic substrate. Journal of Peptide Science, 2011, 17, 569-575.	0.8	3
22	Tubulin photoaffinity labeling study with a plinabulin chemical probe possessing a biotin tag at the oxazole. Bioorganic and Medicinal Chemistry, 2011, 19, 595-602.	1.4	22
23	Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1832-1837.	1.0	7
24	Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2425-2429.	1.0	13
25	Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mtext>P</mml:mtext></mml:mrow><mml:mrow><mml:mn mathvariant="bold">1</mml:mn></mml:mrow><mml:mrow><mml:mo>â€²</mml:mo></mml:mrow></mml:msubsup></mml:mrow></m and P4 positions. Bioorganic and Medicinal Chemistry, 2010, 18, 3175-3186.	1.4	27
26	Anti-microtubule â€˜plinabulinâ€™ chemical probe KPU-244-B3 labeled both Î±- and Î²-tubulin. Bioorganic and Medicinal Chemistry, 2010, 18, 3169-3174.	1.4	33
27	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4836-4839.	1.0	18
28	Tetrapeptides, as smallâ€sized peptidic inhibitors; synthesis and their inhibitory activity against BACE1. Journal of Peptide Science, 2010, 16, 257-262.	0.8	5
29	How Much Binding Affinity Can be Gained by Filling a Cavity?. Chemical Biology and Drug Design, 2010, 75, 143-151.	1.5	47
30	Crystal Growth Procedure of HIV-1 Protease-Inhibitor KNI-272 Complex for Neutron Structural Analysis at 1.9 Ã... Resolution. Crystal Growth and Design, 2010, 10, 2990-2994.	1.4	11
31	Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4641-4646.	3.3	131
32	New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2722-2727.	1.0	49
33	Small-Sized Human Immunodeficiency Virus Type-1 Protease Inhibitors Containing Allophenylnorstatine to Explore the S2â€² Pocket. Journal of Medicinal Chemistry, 2009, 52, 7604-7617.	2.9	24
34	Crystallization and preliminary neutron diffraction studies of HIV-1 protease cocrystallized with inhibitor KNI-272. Acta Crystallographica Section F: Structural Biology Communications, 2008, 64, 1003-1006.	0.7	17
35	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorganic and Medicinal Chemistry, 2008, 16, 10049-10060.	1.4	27
36	Novel non-peptidic and small-sized BACE1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1654-1658.	1.0	46

#	Article	IF	Citations
37	xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si4.gif" overflow="scroll"><mml:mrow><mml:mmultiscripts><mml:mrow><mml:mtext>P</mml:mtext></mml:mrow><mml:mrow><mml:mn>1 /><mml:none /><mml:mrow><mml:mo>â€²</mml:mo></mml:mrow></mml:mmultiscripts></mml:mrow></mml:math>	1.0	40
38	Combination of Non-natural <scp>d</scp>-Amino Acid Derivatives and Allophenylnorstatineâ˜Dimethylthioproline Scaffold in HIV Protease Inhibitors Have High Efficacy in Mutant HIV. Journal of Medicinal Chemistry, 2008, 51, 2992-3004.	2.9	42
39	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3048-3052.	1.0	23
40	Design and synthesis of BACE1 inhibitors containing a novel norstatine derivative (2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyric acid. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1629-1633.	1.0	12
41	Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating d-cysteine derivatives as P2/P3 moieties. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4213-4217.	1.0	25
42	Evaluation of Malarial Protease Plasmepsin Inhibitors Containing Hydroxymethylcarbonyl Isostere. , 2006, , 597-598.		0
43	Structure of the aspartic protease plasmepsin 4 from the malarial parasitePlasmodium malariaebound to an allophenylnorstatine-based inhibitor. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 246-252.	2.5	47
44	Design and synthesis of potent Î²-secretase (BACE1) inhibitors with carboxylic acid bioisosteres. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2380-2386.	1.0	71
45	Î²-Secretase inhibitors: Modification at the P4 position and improvement of inhibitory activity in cultured cells. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4354-4359.	1.0	55
46	Design and Synthesis of Î²-Secretase Inhibitors: Optimization at the P4 and P1â€² Positions. , 2006, , 599-600.		0
47	Design and synthesis of highly active Alzheimerâ€™s Î²-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 211-215.	1.0	98
48	Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases. Biological Chemistry, 2004, 385, 1035-9.	1.2	30
49	Search for substrate-based inhibitors fitting the S2? space of malarial aspartic protease plasmepsin II. Journal of Peptide Science, 2004, 10, 641-647.	0.8	38
50	KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1527-1531.	1.0	70
51	KMI-008, a novel Î²-Secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-State mimic: design and synthesis of substrate-based octapeptides. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4273-4276.	1.0	83
52	Design and synthesis of pseudo-Symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-Hydrazide isostere. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 93-96.	1.0	11
53	High-Affinity Inhibition of a Family ofPlasmodium falciparumProteases by a Designed Adaptive Inhibitorâ€. Biochemistry, 2003, 42, 8459-8464.	1.2	113
54	Analysis of Amide Bond Formation with an Î±-Hydroxy-Î²-amino Acid Derivative, 3-Amino-2-hydroxy-4-phenylbutanoic Acid, as an Acyl Component:Â Byproduction of Homobislactone. Journal of Organic Chemistry, 2001, 66, 5537-5544.	1.7	20